Cancer
Cancer Ongoing 2020 Florida

BR004

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Trial overview

Disease
Breast cancer treatment and diagnosis
Topic
BR004
Description
Primary Objective To determine whether the addition of atezolizumab to a regimen of paclitaxel, pertuzumab, and trastuzumab will improve the progression-free survival (PFS), assessed by investigator using RECIST 1.1 criteria, relative to a regimen of paclitaxel, pertuzumab, trastuzumab, and placebo in patients with newly documented HER2-positive measurable metastatic breast cancer.
Physicians

Dr. Mohammad Jahanzeb

MD, FACP, FASCO

Medical Oncologist

Works at 3 centers.

Dr. Edgardo Santos

MD

Medical Oncologist

Works at 3 centers.